Coumadin

Phase 3Small molecule

Boehringer Ingelheim

Coumadin is one of 90 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

Venous ThrombosisActive, not recruiting

Atrial FibrillationActive, not recruiting

Venous ThromboembolismPhase 2

Active, not recruiting

Venous ThrombosisPreclinical

Active, not recruiting

Atrial FibrillationPhase 3

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Coumadin

Boehringer Ingelheim

Phase 3

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 10

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrial Fibrillation1 trial

Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

Completed·TTexas Cardiac Arrhythmia Research Foundation·Phase 3·NCT01006876·1,584 enrolled

Venous thrombosis1 trial

Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis

Unknown status·FFoundation University Islamabad·N/A·NCT03191305·50 enrolled

Venous Thromboembolism1 trial

Odiparcil For The Prevention Of Venous Thromboembolism

Completed· GSK logo

GSK·Phase 2·NCT00244725·961 enrolled

Midazolam1 trial

A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT04679948·16 enrolled

Anticoagulation1 trial

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

Unknown status·AARYx Therapeutics·Phase 2/3·NCT00691470·600 enrolled

1 more indication

Unspecified1 trial

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

Unknown status·AAgency for Healthcare Research and Quality (AHRQ)·N/A·NCT00484640·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Coumadin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Coumadin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Coumadin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

Coumadin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrial Fibrillation1 trial

Venous thrombosis1 trial

Venous Thromboembolism1 trial

Midazolam1 trial

Anticoagulation1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News